Folgen

  • Additional Advances in ALS Research and Clinical Trials With Richard S. Bedlack, MD, PhD, MS

    Additional Advances in ALS Research and Clinical Trials With Richard S. Bedlack, MD, PhD, MS
    Feb 10 2026
    The ALS treatment landscape is shifting faster than ever, with emerging clinical trial data and advances in gene‑targeted therapies reshaping how healthcare professionals think about disease management and patient support. Now, with encouraging new results from clinical trials and the growing influence of AI‑driven drug discovery, Richard S. Bedlack, MD, PhD, of Duke University School of Medicine, and chair of i3 Health's activity, "Slowing Disease Progression and Optimizing Quality of Life for Patients with ALS, returns to highlight the latest developments that are already informing clinical practice—and bringing renewed optimism to both clinicians and the patients they serve. Click here to view the full activity and claim your free credit: https://bit.ly/4qbRoXh
    Mehr anzeigen Weniger anzeigen
    12 Min.
  • EXPIRING SOON! Schizophrenia Update: Module 4: Applying the Latest Therapeutic Advances to Patient-Centered Care

    EXPIRING SOON! Schizophrenia Update: Module 4: Applying the Latest Therapeutic Advances to Patient-Centered Care
    Feb 2 2026
    Effective schizophrenia management requires a holistic, patient-centered approach tailored to the individual’s unique needs. This final module focuses on integrating evidence-based strategies with shared decision-making to foster recovery. If you missed any previous parts of this series, be sure to listen to Modules 1 through 3 to gain a comprehensive update on the latest research and treatment landscape. Note: This podcast expires on 2/17. Click the link below to claim your CME/NCPD/CPE credit. bit.ly/4oflWWZ
    Mehr anzeigen Weniger anzeigen
    18 Min.
  • EXPIRING SOON! Schizophrenia Update: Module 3: Emerging Treatments for Cognitive Symptoms

    EXPIRING SOON! Schizophrenia Update: Module 3: Emerging Treatments for Cognitive Symptoms
    Feb 2 2026
    Cognitive impairment is a core feature of schizophrenia that contributes heavily to long-term disability. In Module 3, discover current and emerging pharmacologic treatments designed to target cognitive symptoms, alongside psychosocial and lifestyle interventions that enhance functioning. To complete the series, continue to Module 4 for a deep dive into applying these advances to patient-centered care. Note: This podcast expires on 2/17. Click the link below to claim your CME/NCPD/CPE credit. bit.ly/47fkz4p
    Mehr anzeigen Weniger anzeigen
    19 Min.
  • EXPIRING SOON! Schizophrenia Update: Module 2: Advances in Long-Acting Injectables

    EXPIRING SOON! Schizophrenia Update: Module 2: Advances in Long-Acting Injectables
    Feb 2 2026
    Adherence to oral antipsychotics is frequently disrupted by complex dosing schedules and side effects. This module examines the clinical benefits of long-acting injectables (LAIs), including steadier blood concentrations and improved patient tolerance. Learn how the latest LAI formulations can transform treatment adherence and long-term stability. After listening, be sure to move on to Module 3 to learn about emerging treatments for cognitive symptoms. Note: This podcast expires on 2/17. Click the link below to claim your CME/NCPD/CPE credit. bit.ly/436dYa5
    Mehr anzeigen Weniger anzeigen
    21 Min.
  • EXPIRING SOON! Schizophrenia Update: Module 1: Understanding the Evolving Treatment Landscape

    EXPIRING SOON! Schizophrenia Update: Module 1: Understanding the Evolving Treatment Landscape
    Feb 2 2026
    Schizophrenia remains a complex challenge that significantly impacts life expectancy and daily functioning. While dopamine-blocking agents have long been the standard of care, their limitations often leave patients with persistent symptoms. In this module, Dr. Christoph U. Correll explores the shortcomings of current therapies and discusses the latest efforts to optimize treatment strategies. Once you have completed this session, continue your learning journey by tuning into Module 2 to explore advances in long-acting injectables. Note: This podcast expires on 2/17. Click the link below to claim your CME/NCPD/CPE credit. bit.ly/432ICln
    Mehr anzeigen Weniger anzeigen
    41 Min.
  • Additional Advances in Melanoma Research and Clinical Trials With Michael A. Davies, MD, PhD + Module 2

    Additional Advances in Melanoma Research and Clinical Trials With Michael A. Davies, MD, PhD + Module 2
    Jan 27 2026
    The treatment landscape for melanoma continues to evolve at a rapid pace, with new clinical trial data and therapeutic modalities refining how clinicians approach both early-stage and advanced disease. Michael A. Davies, MD, PhD, Professor and Chairman of the Department of Melanoma Medical Oncology at the University of Texas MD Anderson Cancer Center, recently chaired i3 Health’s CME/NCPD/AAPA activity, "Melanoma in Minutes: Evidence-Driven Care for Improved Patient Outcomes." With numerous new developments in melanoma treatment over recent months, Dr. Davies sat down again to share these critical updates that are impacting practice. After the interview, stay tuned to hear module 2 of the full podcast activity. Click the link to complete module 2 and claim your free credit: https://bit.ly/44yO9RB
    Mehr anzeigen Weniger anzeigen
    28 Min.
  • Additional Advances in Melanoma Research and Clinical Trials With Michael A. Davies, MD, PhD + Module 1

    Additional Advances in Melanoma Research and Clinical Trials With Michael A. Davies, MD, PhD + Module 1
    Jan 27 2026
    The treatment landscape for melanoma continues to evolve at a rapid pace, with new clinical trial data and therapeutic modalities refining how clinicians approach both early-stage and advanced disease. Michael A. Davies, MD, PhD, Professor and Chairman of the Department of Melanoma Medical Oncology at the University of Texas MD Anderson Cancer Center, recently chaired i3 Health’s CME/NCPD/AAPA activity, "Melanoma in Minutes: Evidence-Driven Care for Improved Patient Outcomes." With numerous new developments in melanoma treatment over recent months, Dr. Davies sat down again to share these critical updates that are impacting practice. After the interview, stay tuned to hear module 1 of the full podcast activity. Click the link to complete module 1 and claim your free credit: https://bit.ly/4iYmYD2
    Mehr anzeigen Weniger anzeigen
    57 Min.
  • Navigating HER2-Mutant NSCLC Pathology and Management: A Webinar Preview With Helena A. Yu, MD, and Maria Arcila, MD

    Navigating HER2-Mutant NSCLC Pathology and Management: A Webinar Preview With Helena A. Yu, MD, and Maria Arcila, MD
    Dec 19 2025
    Ready to close the gap in HER2-mutant NSCLC care? Join Memorial Sloan Kettering experts Helena A. Yu, MD, and Maria Arcila, MD, for a live webinar on optimizing HER2 testing and integrating the latest targeted therapies into your practice. They’ll walk through how to improve detection and ensure your patients are getting the most effective, up-to-date treatments available. You can catch the live session on either of these dates: Wednesday, January 8 at 5:00 pm ET: bit.ly/4iZxnA0 Monday, January 26 at 5:00 pm ET: bit.ly/4qALw9J
    Mehr anzeigen Weniger anzeigen
    7 Min.